Dr. Timmer received his board accreditation in clinical pharmacology in 1999 after residencies in prestigious institutions including the department of clinical pharmacology at the University Hospital Mannheim.
For the next four years he served as project leader of early clinical development for Byk Gulden (Altana), where he spearheaded the clinical development of two respiratory compounds in their early development stages. In this role he was deeply involved in the planning, organization, performance, analysis, and reporting of some 40 clinical studies, including preparation of expert reports for submission and representation to the US FDA.
In the following six years Dr. Timmer gained further expertise in respiratory clinical trials serving as clinical trial leader and project manager for Boehringer Ingelheim, mainly in charge of the conduct of phase II-IV respiratory clinical studies.
Prior to joining Inamed Dr. Timmer served as manager and medical director for a CRO in Mannheim, where he also supervised the conduct of phase I/IIa in-house trials performed in healthy subjects and patients. In this context he reviewed numerous non-clinical data and contents of IMPDs, provided scientific advice relating to pharmacological and toxicological data including calculation of the safe starting dose. Moreover, he was entrusted with the interpretation of study results in collaboration with DMPK specialists and biostatisticians, and prepared and reviewed numerous study protocols and clinical trial reports.
In his role as CMO and CEO of Inamed Dr. Timmer further fortifies Inamed's strong team of scientific, medical and inhalation experts by conducting feasibility assessments and providing expert advice and solutions for ongoing clinical projects. He will also be serving clients with scientific consulting and as a representative to regulatory authorities. Moreover, he strengthens Inamed's recruitment strategy of special patient populations, serve as liaison to health care providers and clinical specialists, act as coordinating investigator for multi-center studies, respond to questions from health authorities and IRB/Ethics Committees, and further optimize project planning and internal resource allocation in the best interest of Inamed's valued customers.
To date, Dr. Timmer has served as principal investigator for more than 200 clinical trials and has authored more than 30 peer-reviewed papers and lectures in a wide range of scientific disciplines and therapeutic areas which include clinical pharmacology, respiratory, allergy, diabetology, gastroenterology, and cardiology.